

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 September 2005 (15.09.2005)

PCT

(10) International Publication Number
WO 2005/085260 A1

(51) International Patent Classification⁷: **C07D 519/00**,
A61K 31/5517, A61P 35/00, 31/04 // (C07D 519/00,
487:00, 487:00)

(74) Agents: **WATSON, Robert** et al.; Mewburn Ellis LLP,
York House, 23 Kingsway, London Greater London WC2B
6HP (GB).

(21) International Application Number:
PCT/GB2005/000915

(22) International Filing Date: 9 March 2005 (09.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0405319.5 9 March 2004 (09.03.2004) GB
0412409.5 3 June 2004 (03.06.2004) GB

(71) Applicant (for all designated States except US):
SPIROGEN LIMITED [GB/GB]; 79 George Street,
Ryde, Isle of Wight PO33 2JF (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HOWARD, Philip
Wilson** [GB/GB]; 3 Westbourne Mews, The Maltings,
St Albans, Hertfordshire AL1 1LS (GB). **GREG-
SON, Stephen, John** [GB/GB]; 6 Warepoint Drive,
Thamesmead, London Greater London SE28 OHJ (GB).
TAYLOR, Peter William [GB/GB]; School of Pharmacy,
29/39 Brunswick Square, London Greater London WC1N
1AX (GB). **THURSTON, David Edwin** [GB/GB]; 4
Severn Close, Downend, Fareham Hampshire PO16 8QT
(GB). **HADJIVASSILEVA, Tsveta Stepanova** [BG/GB];
School of Pharmacy, 29/39 Brunswick Square, London
Greater London WC1N 1AX (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PYRROLOBENZODIAZEPINES



(57) Abstract: A compound of formula (I) and salts and solvates thereof, wherein: R¹⁰ is a nitrogen protecting group and R¹¹ is either OH or O-R¹², wherein R¹² is an oxygen protecting group, or R¹⁰ and R¹¹ together form a double bond between N10 and C11; and R^{10'} and R^{11'} are selected from the same options as R¹⁰ and R¹¹ respectively.



WO 2005/085260 A1


PYRROLOBENZODIAZEPINES

The present invention relates to a specific pyrrolobenzodiazepine (PBD) dimer with C2-exo unsaturation.

5


Background to the invention*Pyrrolobenzodiazepines*

Some pyrrolobenzodiazepines (PBDs) have the ability to recognise and bond to specific sequences of DNA; the preferred sequence is PuGpu. The first PBD antitumour antibiotic, anthramycin, was discovered in 1965 (Leimgruber, et al., *J. Am. Chem. Soc.*, **87**, 5793-5795 (1965); Leimgruber, et al., *J. Am. Chem. Soc.*, **87**, 5791-5793 (1965)). Since then, a number of naturally occurring PBDs have been reported, and over 10 synthetic routes have been developed to a variety of analogues (Thurston, et al., *Chem. Rev.* **1994**, 433-465 (1994)). Family members include abbeymycin (Hochlowski, et al., *J. Antibiotics*, **40**, 145-148 (1987)), chicamycin (Konishi, et al., *J. Antibiotics*, **37**, 200-206 (1984)), DC-81 (Japanese Patent 58-180 487; Thurston, et al., *Chem. Brit.*, **26**, 767-772 (1990); Bose, et al., *Tetrahedron*, **48**, 751-758 (1992)), mazethramycin (Kuminoto, et al., *J. Antibiotics*, **33**, 665-667 (1980)), neothramycins A and B (Takeuchi, et al., *J. Antibiotics*, **29**, 93-96 (1976)), porothramycin (Tsunakawa, et al., *J. Antibiotics*, **41**, 1366-1373 (1988)), prothracarcin (Shimizu, et al., *J. Antibiotics*, **29**, 2492-2503 (1982); Langley and Thurston, *J. Org. Chem.*, **52**, 91-97 (1987)), sibanomicin (DC-102) (Hara, et al., *J. Antibiotics*, **41**, 702-704 (1988); Itoh, et al., *J. Antibiotics*, **41**, 1281-1284 (1988)), sibiromycin (Leber, et al., *J. Am. Chem. Soc.*, **110**, 2992-2993 (1988)) and tomamycin (Arima, et al., *J. Antibiotics*, **25**, 437-444 (1972)). PBDs are of the general structure:



They differ in the number, type and position of substituents, in both their aromatic A rings and pyrrolo C rings, and in the degree of saturation of the C ring. In the B-ring there is either an imine (N=C), a carbinolamine (NH-CH(OH)), or a carbinolamine methyl ether (NH-CH(OMe)) at the N10-C11 position which is the electrophilic centre responsible for alkylating DNA. All of the known natural products have an (S)-configuration at the chiral C11a position which provides them with a right-handed twist when viewed from the C ring towards the A ring. This gives them the appropriate three-dimensional shape for isohelicity with the minor groove of B-form DNA, leading to a snug fit at the binding site (Kohn, In *Antibiotics III*. Springer-Verlag, New York, pp. 3-11 (1975); Hurley and Needham-VanDevanter, *Acc. Chem. Res.*, **19**, 230-237 (1986)). Their ability to form an adduct in the minor groove, enables them to interfere with DNA processing, hence their use as antitumour agents.

In WO 93/18045, some of the present inventors disclosed the following compound (Example 6):



The final compound produced was a mixture of the E-, E- form, the Z-, Z- form and the E-, Z- forms as a result of the synthesis method used. Extrapolating from the last compound for which the amount of different geometric isomers was measured, the final compound would likely have the following proportions of geometric isomers:

Geometric isomers at C2/C2'	Amount (%)
E-, E-	42
E-, Z-	46
Z-, Z-	12

Gram-positive bacteria

Infectious diseases are a leading cause of mortality and morbidity worldwide. Our ability to treat effectively a range of

bacterial infections rose dramatically following the introduction of penicillin and other antibiotics, but multi-drug resistance has emerged as a serious threat to efforts to continue to keep infectious diseases under control.

5

Two of the most serious pathogens associated with drug resistance are methicillin resistant *Staphylococcus aureus* (MRSA) and vancomycin resistant enterococci (VRE).

10

MRSA has become one of the most problematic pathogens in humans not only in nosocomial but also recently in community-acquired infections (Tadashi Baba, et al., *The Lancet*, **359**, 1819-1827 (2002); Enright, M.C., *Current Opinion in Pharmacology*, **3**, 1-6 (2003)). *S.aureus* harmlessly colonises the nasal cavity of some

15

30-40% of the population and may also survive on dry skin for example on the hands. Health care workers and hospital staff may be carriers and may unwittingly infect patients under their care.

S.aureus, an opportunistic pathogen, is of concern in immunocompromised people, prone to infection. It may infect many

20

sites postoperatively if contaminated surgery equipment is used on, for example, open wounds. Blood, heart, bones and joints are also prime tissue-targets of infection. Furthermore toxic shock syndrome, pneumonia and food-poisoning contribute to the wide-spectrum of pathogenicity this organism causes. *S.aureus*

25

infections had been treated successfully with potent antibiotics in the past, however the emergence of multi-drug resistance has limited opportunities to successfully treat these infections.

VRE account for nosocomial infections and is currently a major problem of many healthcare institutions. Although there are

30

several members in the *Enterococcus* family, only two are usually associated with the high morbidity and mortality in hospitals, namely *E.faecalis* and *E.faecium*. Enterococci are part of the normal gastrointestinal tract flora and are carried by healthy individuals. Although many hospital patients may be colonised


35

with VRE, this does not necessarily lead to infection. VRE infections tend to occur in immunocompromised and seriously ill

patients such as those in intensive care units. It has been difficult to establish exactly how much VRE contributes to mortality rates as there are usually many other concomitant infections present in infected patients. In many cases, severe underlying diseases in patients are likely to be the sole cause of death not linked to VRE. The tissues affected are usually the urinary tract, surgical sites, blood and abdominal sites. In addition, endocarditis is a serious infection resulting as a consequence of VRE bacteraemia. The mode of transmission of VRE is similar to that of MRSA. Direct skin-to skin contact with colonised health care workers and contaminated surgical equipment seem to be the leading factors. It appears that the bacteria not only survive on the hands and arms of health workers but may also remain on bed linen and hospital beds as well as other surrounding objects for several days.

Disclosure of the invention

In a first aspect, the invention comprises a compound of formula I:



and salts and solvates thereof, wherein:

R^{10} is a nitrogen protecting group and R^{11} is either OH or O- R^{12} , wherein R^{12} is an oxygen protecting group, or R^{10} and R^{11} together form a double bond between N10 and C11; and $R^{10'}$ and $R^{11'}$ are selected from the same options as R^{10} and R^{11} respectively.

It is preferred that $R^{10'}$ and $R^{11'}$ are the same as R^{10} and R^{11} respectively.

In a second aspect, the invention comprises the synthesis of a compound of formula I.

5 In a third aspect, the invention comprises a compound of formula I and pharmaceutically acceptable salts and solvates thereof, for use in a method of therapy.

10 In a fourth aspect, the invention comprises a pharmaceutical composition comprising a compound of formula I and pharmaceutically acceptable salts and solvates thereof, and a pharmaceutically acceptable excipient.


15 In a fifth aspect, the invention comprises the use of a compound of formula I and pharmaceutically acceptable salts and solvates thereof, in the manufacture of a medicament for the treatment of a gene-based disease.

20 In a sixth aspect, the invention comprises a method for the treatment of a gene-based disease, comprising administering to a subject suffering from a gene-based disease a therapeutically-effective amount of a compound of formula I or pharmaceutically acceptable salts and solvates thereof.

Definitions

25 *Nitrogen protecting groups*


Nitrogen protecting groups are well known in the art. Preferred nitrogen protecting groups are carbamate protecting groups that have the general formula:




30 A large number of possible carbamate nitrogen protecting groups are listed on pages 503 to 549 of Greene, T.W. and Wuts, G.M., Protective Groups in Organic Synthesis, 3rd Edition, John Wiley & Sons, Inc., 1999, which is incorporated herein by reference.

Particularly preferred protecting groups include Alloc, Troc, Teoc, BOC, Doc, Hoc, TcBOC, Fmoc, 1-Adoc and 2-Adoc.


Also suitable for use in the present invention are nitrogen
 5 protecting groups which can be removed *in vivo* (e.g. enzymatically, using light) as described in WO 00/12507, which is incorporated herein by reference. Examples of these protecting groups include:




10 , which is nitroreductase labile (e.g. using ADEPT/GDEPT);



and



, which are photolabile; and



15 which is glutathione labile (e.g. using NPEPT).

Oxygen protecting groups

Oxygen protecting groups are well known in the art. A large
 number of suitable groups are described on pages 23 to 200 of
 20 Greene, T.W. and Wuts, G.M., Protective Groups in Organic
 Synthesis, 3rd Edition, John Wiley & Sons, Inc., 1999, which is
 incorporated herein by reference.

Classes of particular interest include silyl ethers, methyl
 25 ethers, alkyl ethers, benzyl ethers, esters, benzoates,
 carbonates, and sulfonates.

Substituents

The phrase "optionally substituted" as used herein, pertains to a parent group which may be unsubstituted or which may be substituted.

5

Unless otherwise specified, the term "substituted" as used herein, pertains to a parent group which bears one or more substituents. The term "substituent" is used herein in the conventional sense and refers to a chemical moiety which is covalently attached to, or if appropriate, fused to, a parent group. A wide variety of substituents are well known, and methods for their formation and introduction into a variety of parent groups are also well known.

10

15 Examples of substituents are described in more detail below.

C₁₋₇ alkyl: The term "C₁₋₇ alkyl" as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of a hydrocarbon compound having from 1 to 7 carbon atoms, which may be aliphatic or alicyclic, and which may be saturated or unsaturated (e.g. partially unsaturated, fully unsaturated). Thus, the term "alkyl" includes the sub-classes alkenyl, alkynyl, cycloalkyl, etc., discussed below.

20

25 Examples of saturated alkyl groups include, but are not limited to, methyl (C₁), ethyl (C₂), propyl (C₃), butyl (C₄), pentyl (C₅), hexyl (C₆) and heptyl (C₇).

Examples of saturated linear alkyl groups include, but are not limited to, methyl (C₁), ethyl (C₂), n-propyl (C₃), n-butyl (C₄), n-pentyl (amyl) (C₅), n-hexyl (C₆) and n-heptyl (C₇).

30

Examples of saturated branched alkyl groups include iso-propyl (C₃), iso-butyl (C₄), sec-butyl (C₄), tert-butyl (C₄), iso-pentyl (C₅), and neo-pentyl (C₅).

35

C₂₋₇ Alkenyl: The term "C₂₋₇ alkenyl" as used herein, pertains to an alkyl group having one or more carbon-carbon double bonds.

5 Examples of unsaturated alkenyl groups include, but are not limited to, ethenyl (vinyl, -CH=CH₂), 1-propenyl (-CH=CH-CH₃), 2-propenyl (allyl, -CH-CH=CH₂), isopropenyl (1-methylvinyl, -C(CH₃)=CH₂), butenyl (C₄), pentenyl (C₅), and hexenyl (C₆).

10 C₂₋₇ alkynyl: The term "C₂₋₇ alkynyl" as used herein, pertains to an alkyl group having one or more carbon-carbon triple bonds.

15 Examples of unsaturated alkynyl groups include, but are not limited to, ethynyl (ethinyl, -C≡CH) and 2-propynyl (propargyl, -CH₂-C≡CH).

20 C₃₋₇ cycloalkyl: The term "C₃₋₇ cycloalkyl" as used herein, pertains to an alkyl group which is also a cyclyl group; that is, a monovalent moiety obtained by removing a hydrogen atom from an alicyclic ring atom of a cyclic hydrocarbon (carbocyclic) compound, which moiety has from 3 to 7 carbon atoms, including from 3 to 7 ring atoms.

Examples of cycloalkyl groups include, but are not limited to, those derived from:

25 saturated monocyclic hydrocarbon compounds:

cyclopropane (C₃), cyclobutane (C₄), cyclopentane (C₅), cyclohexane (C₆), cycloheptane (C₇), methylcyclopropane (C₄), dimethylcyclopropane (C₅), methylcyclobutane (C₅), dimethylcyclobutane (C₆), methylcyclopentane (C₆),
30 dimethylcyclopentane (C₇) and methylcyclohexane (C₇);

unsaturated monocyclic hydrocarbon compounds:

cyclopropene (C₃), cyclobutene (C₄), cyclopentene (C₅), cyclohexene (C₆), methylcyclopropene (C₄), dimethylcyclopropene (C₅), methylcyclobutene (C₅), dimethylcyclobutene (C₆),
35 methylcyclopentene (C₆), dimethylcyclopentene (C₇) and methylcyclohexene (C₇); and

saturated polycyclic hydrocarbon compounds:

norcarane (C₇), norpinane (C₇), norbornane (C₇).

C₃₋₂₀ heterocyclyl: The term "C₃₋₂₀ heterocyclyl" as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a ring atom of a heterocyclic compound, which moiety has from 3 to 20 ring atoms, of which from 1 to 10 are ring heteroatoms. Preferably, each ring has from 3 to 7 ring atoms, of which from 1 to 4 are ring heteroatoms.

In this context, the prefixes (e.g. C₃₋₂₀, C₃₋₇, C₅₋₆, etc.) denote the number of ring atoms, or range of number of ring atoms, whether carbon atoms or heteroatoms. For example, the term "C₅₋₆heterocyclyl", as used herein, pertains to a heterocyclyl group having 5 or 6 ring atoms.

15

Examples of monocyclic heterocyclyl groups include, but are not limited to, those derived from:

N₁: aziridine (C₃), azetidine (C₄), pyrrolidine

(tetrahydropyrrole) (C₅), pyrroline (e.g., 3-pyrroline, 2,5-dihydropyrrole) (C₅), 2H-pyrrole or 3H-pyrrole (isopyrrole, isoazole) (C₅), piperidine (C₆), dihydropyridine (C₆), tetrahydropyridine (C₆), azepine (C₇);

O₁: oxirane (C₃), oxetane (C₄), oxolane (tetrahydrofuran) (C₅), oxole (dihydrofuran) (C₅), oxane (tetrahydropyran) (C₆), dihydropyran (C₆), pyran (C₆), oxepin (C₇);

S₁: thiirane (C₃), thietane (C₄), thiolane (tetrahydrothiophene) (C₅), thiane (tetrahydrothiopyran) (C₆), thiepane (C₇);

O₂: dioxolane (C₅), dioxane (C₆), and dioxepane (C₇);

O₃: trioxane (C₆);

N₂: imidazolidine (C₅), pyrazolidine (diazolidine) (C₅), imidazoline (C₅), pyrazoline (dihydropyrazole) (C₅), piperazine (C₆);

N₁O₁: tetrahydrooxazole (C₅), dihydrooxazole (C₅), tetrahydroisoxazole (C₅), dihydroisoxazole (C₅), morpholine (C₆), tetrahydrooxazine (C₆), dihydrooxazine (C₆), oxazine (C₆);

N₁S₁: thiazoline (C₅), thiazolidine (C₅), thiomorpholine (C₆);

N₂O₁: oxadiazine (C₆);

O₁S₁: oxathiole (C₅) and oxathiane (thioxane) (C₆); and,
N₁O₁S₁: oxathiazine (C₆).

Examples of substituted monocyclic heterocyclyl groups include
5 those derived from saccharides, in cyclic form, for example,
furanoses (C₅), such as arabinofuranose, lyxofuranose,
ribofuranose, and xylofuranse, and pyranoses (C₆), such as
allopylanose, altropylanose, glucopyranose, mannopyranose,
gulopyranose, idopyranose, galactopyranose, and talopyranose.

10

C₅₋₂₀ aryl: The term "C₅₋₂₀ aryl", as used herein, pertains to a
monovalent moiety obtained by removing a hydrogen atom from an
aromatic ring atom of an aromatic compound, which moiety has from
3 to 20 ring atoms. Preferably, each ring has from 5 to 7 ring
15 atoms.

15

In this context, the prefixes (e.g. C₃₋₂₀, C₅₋₇, C₅₋₆, etc.) denote
the number of ring atoms, or range of number of ring atoms,
whether carbon atoms or heteroatoms. For example, the term "C₅₋₆
20 aryl" as used herein, pertains to an aryl group having 5 or 6
ring atoms.

20

The ring atoms may be all carbon atoms, as in "carboaryl groups".
Examples of carboaryl groups include, but are not limited to,
25 those derived from benzene (i.e. phenyl) (C₆), naphthalene (C₁₀),
azulene (C₁₀), anthracene (C₁₄), phenanthrene (C₁₄), naphthacene
(C₁₈), and pyrene (C₁₆).

25

Examples of aryl groups which comprise fused rings, at least one
30 of which is an aromatic ring, include, but are not limited to,
groups derived from indane (e.g. 2,3-dihydro-1H-indene) (C₉),
indene (C₉), isoindene (C₉), tetraline
(1,2,3,4-tetrahydronaphthalene (C₁₀), acenaphthene (C₁₂), fluorene
(C₁₃), phenalene (C₁₃), acephenanthrene (C₁₅), and aceanthrene
35 (C₁₆).

35

Alternatively, the ring atoms may include one or more heteroatoms, as in "heteroaryl groups". Examples of monocyclic heteroaryl groups include, but are not limited to, those derived from:

- 5 N₁: pyrrole (azole) (C₅), pyridine (azine) (C₆);
 O₁: furan (oxole) (C₅);
 S₁: thiophene (thiole) (C₅);
 N₁O₁: oxazole (C₅), isoxazole (C₅), isoxazine (C₆);
 N₂O₁: oxadiazole (furazan) (C₅);
 10 N₃O₁: oxatriazole (C₅);
 N₁S₁: thiazole (C₅), isothiazole (C₅);
 N₂: imidazole (1,3-diazole) (C₅), pyrazole (1,2-diazole) (C₅),
 pyridazine (1,2-diazine) (C₆), pyrimidine (1,3-diazine) (C₆)
 (e.g., cytosine, thymine, uracil), pyrazine (1,4-diazine) (C₆);
 15 N₃: triazole (C₅), triazine (C₆); and,
 N₄: tetrazole (C₅).

Examples of heteroaryl which comprise fused rings, include, but are not limited to:

- 20 C₉ (with 2 fused rings) derived from benzofuran (O₁),
 isobenzofuran (O₁), indole (N₁), isoindole (N₁), indolizine (N₁),
 indoline (N₁), isoindoline (N₁), purine (N₄) (e.g., adenine,
 guanine), benzimidazole (N₂), indazole (N₂), benzoxazole (N₁O₁),
 benzisoxazole (N₁O₁), benzodioxole (O₂), benzofurazan (N₂O₁),
 25 benzotriazole (N₃), benzothiofuran (S₁), benzothiazole (N₁S₁),
 benzothiadiaazole (N₂S);
 C₁₀ (with 2 fused rings) derived from chromene (O₁),
 isochromene (O₁), chroman (O₁), isochroman (O₁), benzodioxan (O₂),
 quinoline (N₁), isoquinoline (N₁), quinolizine (N₁), benzoxazine
 30 (N₁O₁), benzodiazine (N₂), pyridopyridine (N₂), quinoxaline (N₂),
 quinazoline (N₂), cinnoline (N₂), phthalazine (N₂), naphthyridine
 (N₂), pteridine (N₄);
 C₁₁ (with 2 fused rings) derived from benzodiazepine (N₂);
 C₁₃ (with 3 fused rings) derived from carbazole (N₁),
 35 dibenzofuran (O₁), dibenzothiophene (S₁), carboline (N₂),
 perimidine (N₂), pyridoindole (N₂); and,

C₁₄ (with 3 fused rings) derived from acridine (N₁), xanthene (O₁), thioxanthene (S₁), oxanthrene (O₂), phenoxathiin (O₁S₁), phenazine (N₂), phenoxazine (N₁O₁), phenothiazine (N₁S₁), thianthrene (S₂), phenanthridine (N₁), phenanthroline (N₂),
5 phenazine (N₂).

The above groups, whether alone or part of another substituent, may themselves optionally be substituted with one or more groups selected from themselves and the additional substituents listed
10 below.

Halo: -F, -Cl, -Br, and -I.

Hydroxy: -OH.

15

Ether: -OR, wherein R is an ether substituent, for example, a C₁₋₇ alkyl group (also referred to as a C₁₋₇ alkoxy group, discussed below), a C₃₋₂₀ heterocyclyl group (also referred to as a C₃₋₂₀ heterocyclyloxy group), or a C₅₋₂₀ aryl group (also referred to as
20 a C₅₋₂₀ aryloxy group), preferably a C₁₋₇alkyl group.

Alkoxy: -OR, wherein R is an alkyl group, for example, a C₁₋₇ alkyl group. Examples of C₁₋₇ alkoxy groups include, but are not limited to, -OMe (methoxy), -OEt (ethoxy), -O(nPr) (n-propoxy), -
25 O(iPr) (isopropoxy), -O(nBu) (n-butoxy), -O(sBu) (sec-butoxy), -O(iBu) (isobutoxy), and -O(tBu) (tert-butoxy).

Acetal: -CH(OR¹)(OR²), wherein R¹ and R² are independently acetal substituents, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group, or, in
30 the case of a "cyclic" acetal group, R¹ and R², taken together with the two oxygen atoms to which they are attached, and the carbon atoms to which they are attached, form a heterocyclic ring having from 4 to 8 ring atoms. Examples of acetal groups
35 include, but are not limited to, -CH(OMe)₂, -CH(OEt)₂, and -CH(OMe)(OEt).

Hemiacetal: $-\text{CH}(\text{OH})(\text{OR}^1)$, wherein R^1 is a hemiacetal substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of hemiacetal groups include, but are not limited to, $-\text{CH}(\text{OH})(\text{OMe})$ and $-\text{CH}(\text{OH})(\text{OEt})$.

Ketal: $-\text{CR}(\text{OR}^1)(\text{OR}^2)$, where R^1 and R^2 are as defined for acetals, and R is a ketal substituent other than hydrogen, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples ketal groups include, but are not limited to, $-\text{C}(\text{Me})(\text{OMe})_2$, $-\text{C}(\text{Me})(\text{OEt})_2$, $-\text{C}(\text{Me})(\text{OMe})(\text{OEt})$, $-\text{C}(\text{Et})(\text{OMe})_2$, $-\text{C}(\text{Et})(\text{OEt})_2$, and $-\text{C}(\text{Et})(\text{OMe})(\text{OEt})$.

Hemiketal: $-\text{CR}(\text{OH})(\text{OR}^1)$, where R^1 is as defined for hemiacetals, and R is a hemiketal substituent other than hydrogen, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of hemiacetal groups include, but are not limited to, $-\text{C}(\text{Me})(\text{OH})(\text{OMe})$, $-\text{C}(\text{Et})(\text{OH})(\text{OMe})$, $-\text{C}(\text{Me})(\text{OH})(\text{OEt})$, and $-\text{C}(\text{Et})(\text{OH})(\text{OEt})$.

Oxo (keto, -one): $=\text{O}$.

Thione (thioketone): $=\text{S}$.

Imino (imine): $=\text{NR}$, wherein R is an imino substituent, for example, hydrogen, C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably hydrogen or a C_{1-7} alkyl group. Examples of ester groups include, but are not limited to, $=\text{NH}$, $=\text{NMe}$, $=\text{NEt}$, and $=\text{NPh}$.

Formyl (carbaldehyde, carboxaldehyde): $-\text{C}(=\text{O})\text{H}$.

Acyl (keto): $-\text{C}(=\text{O})\text{R}$, wherein R is an acyl substituent, for example, a C_{1-7} alkyl group (also referred to as C_{1-7} alkylacyl or C_{1-7} alkanoyl), a C_{3-20} heterocyclyl group (also referred to as C_{3-20} heterocyclylacyl), or a C_{5-20} aryl group (also referred to as C_{5-20} arylacyl), preferably a C_{1-7} alkyl group. Examples of acyl groups

include, but are not limited to, $-C(=O)CH_3$ (acetyl), $-C(=O)CH_2CH_3$ (propionyl), $-C(=O)C(CH_3)_3$ (t-butyryl), and $-C(=O)Ph$ (benzoyl, phenone).

5 Carboxy (carboxylic acid): $-C(=O)OH$.

Thiocarboxy (thiocarboxylic acid): $-C(=S)SH$.

Thiolocarboxy (thiolocarboxylic acid): $-C(=O)SH$.

10

Thionocarboxy (thionocarboxylic acid): $-C(=S)OH$.

Imidic acid: $-C(=NH)OH$.

15 Hydroxamic acid: $-C(=NOH)OH$.

Ester (carboxylate, carboxylic acid ester, oxycarbonyl):

$-C(=O)OR$, wherein R is an ester substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of ester groups include, but are not limited to, $-C(=O)OCH_3$, $-C(=O)OCH_2CH_3$, $-C(=O)OC(CH_3)_3$, and $-C(=O)OPh$.

20

Acyloxy (reverse ester): $-OC(=O)R$, wherein R is an acyloxy substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of acyloxy groups include, but are not limited to, $-OC(=O)CH_3$ (acetoxy), $-OC(=O)CH_2CH_3$, $-OC(=O)C(CH_3)_3$, $-OC(=O)Ph$, and $-OC(=O)CH_2Ph$.

25

30

Oxycarboxyloxy: $-OC(=O)OR$, wherein R is an ester substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of ester groups include, but are not limited to, $-OC(=O)OCH_3$,

35 $-OC(=O)OCH_2CH_3$, $-OC(=O)OC(CH_3)_3$, and $-OC(=O)OPh$.

Amino: $-NR^1R^2$, wherein R^1 and R^2 are independently amino substituents, for example, hydrogen, a C_{1-7} alkyl group (also referred to as C_{1-7} alkylamino or di- C_{1-7} alkylamino), a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably H or a C_{1-7} alkyl group, or, in the case of a "cyclic" amino group, R^1 and R^2 , taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 4 to 8 ring atoms. Amino groups may be primary ($-NH_2$), secondary ($-NHR^1$), or tertiary ($-NHR^1R^2$), and in cationic form, may be quaternary ($-^+NR^1R^2R^3$).


Examples of amino groups include, but are not limited to, $-NH_2$, $-NHCH_3$, $-NHC(CH_3)_2$, $-N(CH_3)_2$, $-N(CH_2CH_3)_2$, and $-NHPh$. Examples of cyclic amino groups include, but are not limited to, aziridino, azetidino, pyrrolidino, piperidino, piperazino, morpholino, and thiomorpholino.

Amido (carbamoyl, carbamyl, aminocarbonyl, carboxamide): $-C(=O)NR^1R^2$, wherein R^1 and R^2 are independently amino substituents, as defined for amino groups. Examples of amido groups include, but are not limited to, $-C(=O)NH_2$, $-C(=O)NHCH_3$, $-C(=O)N(CH_3)_2$, $-C(=O)NHCH_2CH_3$, and $-C(=O)N(CH_2CH_3)_2$, as well as amido groups in which R^1 and R^2 , together with the nitrogen atom to which they are attached, form a heterocyclic structure as in, for example, piperidinocarbonyl, morpholinocarbonyl, thiomorpholinocarbonyl, and piperazinocarbonyl.

Thioamido (thiocarbamyl): $-C(=S)NR^1R^2$, wherein R^1 and R^2 are independently amino substituents, as defined for amino groups. Examples of amido groups include, but are not limited to, $-C(=S)NH_2$, $-C(=S)NHCH_3$, $-C(=S)N(CH_3)_2$, and $-C(=S)NHCH_2CH_3$.

Acylamido (acylamino): $-NR^1C(=O)R^2$, wherein R^1 is an amide substituent, for example, hydrogen, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably hydrogen or a C_{1-7} alkyl group, and R^2 is an acyl substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably hydrogen or a C_{1-7} alkyl group. Examples of acylamide groups include, but are not limited to, $-NHC(=O)CH_3$,

-NHC(=O)CH₂CH₃, and -NHC(=O)Ph. R¹ and R² may together form a cyclic structure, as in, for example, succinimidyl, maleimidyl, and phthalimidyl:



5

Aminocarbonyloxy: -OC(=O)NR¹R², wherein R¹ and R² are independently amino substituents, as defined for amino groups. Examples of aminocarbonyloxy groups include, but are not limited to, -OC(=O)NH₂, -OC(=O)NHMe, -OC(=O)NMe₂, and -OC(=O)NEt₂.

10


Ureido: -N(R¹)CONR²R³ wherein R² and R³ are independently amino substituents, as defined for amino groups, and R¹ is a ureido substituent, for example, hydrogen, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably hydrogen or a C₁₋₇ alkyl group. Examples of ureido groups include, but are not limited to, -NHCONH₂, -NHCONHMe, -NHCONHEt, -NHCONMe₂, -NHCONEt₂, -NMeCONH₂, -NMeCONHMe, -NMeCONHEt, -NMeCONMe₂, and -NMeCONEt₂.

15

Guanidino: -NH-C(=NH)NH₂.

20

Tetrazolyl: a five membered aromatic ring having four nitrogen atoms and one carbon atom,



25 Imino: =NR, wherein R is an imino substituent, for example, for example, hydrogen, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably H or a C₁₋₇alkyl group. Examples of imino groups include, but are not limited to, =NH, =NMe, and =NEt.

30

Amidine (amidino): $-C(=NR)NR_2$, wherein each R is an amidine substituent, for example, hydrogen, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably H or a C_{1-7} alkyl group. Examples of amidine groups include, but are not
5 limited to, $-C(=NH)NH_2$, $-C(=NH)NMe_2$, and $-C(=NMe)NMe_2$.

Nitro: $-NO_2$.

Nitroso: $-NO$.

10

Azido: $-N_3$.

Cyano (nitrile, carbonitrile): $-CN$.

15

Isocyano: $-NC$.

Cyanato: $-OCN$.

Isocyanato: $-NCO$.

20

Thiocyano (thiocyanato): $-SCN$.

Isothiocyano (isothiocyano): $-NCS$.

25

Sulfhydryl (thiol, mercapto): $-SH$.

Thioether (sulfide): $-SR$, wherein R is a thioether substituent, for example, a C_{1-7} alkyl group (also referred to as a C_{1-7} alkylthio group), a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably
30 a C_{1-7} alkyl group. Examples of C_{1-7} alkylthio groups include, but are not limited to, $-SCH_3$ and $-SCH_2CH_3$.

Disulfide: $-SS-R$, wherein R is a disulfide substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20}
35 aryl group, preferably a C_{1-7} alkyl group (also referred to herein as C_{1-7} alkyl disulfide). Examples of C_{1-7} alkyl disulfide groups include, but are not limited to, $-SSCH_3$ and $-SSCH_2CH_3$.

Sulfine (sulfinyl, sulfoxide): $-S(=O)R$, wherein R is a sulfine substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group.

5 Examples of sulfine groups include, but are not limited to, $-S(=O)CH_3$ and $-S(=O)CH_2CH_3$.

Sulfone (sulfonyl): $-S(=O)_2R$, wherein R is a sulfone substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a
10 C_{5-20} aryl group, preferably a C_{1-7} alkyl group, including, for example, a fluorinated or perfluorinated C_{1-7} alkyl group. Examples of sulfone groups include, but are not limited to, $-S(=O)_2CH_3$ (methanesulfonyl, mesyl), $-S(=O)_2CF_3$ (triflyl), $-S(=O)_2CH_2CH_3$ (esyl), $-S(=O)_2C_4F_9$ (nonafllyl), $-S(=O)_2CH_2CF_3$
15 (tresyl), $-S(=O)_2CH_2CH_2NH_2$ (tauryl), $-S(=O)_2Ph$ (phenylsulfonyl, besyl), 4-methylphenylsulfonyl (tosyl), 4-chlorophenylsulfonyl (closyl), 4-bromophenylsulfonyl (brosyl), 4-nitrophenyl (nosyl), 2-naphthalenesulfonate (napsyl), and 5-dimethylamino-naphthalen-
1-ylsulfonate (dansyl).

20

Sulfinic acid (sulfino): $-S(=O)OH$, $-SO_2H$.

Sulfonic acid (sulfo): $-S(=O)_2OH$, $-SO_3H$.

25 Sulfinate (sulfinic acid ester): $-S(=O)OR$; wherein R is a sulfinate substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of sulfinate groups include, but are not limited to, $-S(=O)OCH_3$ (methoxysulfinyl; methyl sulfinate) and
30 $-S(=O)OCH_2CH_3$ (ethoxysulfinyl; ethyl sulfinate).

Sulfonate (sulfonic acid ester): $-S(=O)_2OR$, wherein R is a sulfonate substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl
35 group. Examples of sulfonate groups include, but are not limited to, $-S(=O)_2OCH_3$ (methoxysulfonyl; methyl sulfonate) and $-S(=O)_2OCH_2CH_3$ (ethoxysulfonyl; ethyl sulfonate).

Sulfinyloxy: $-\text{OS}(=\text{O})\text{R}$, wherein R is a sulfinyloxy substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of
5 sulfinyloxy groups include, but are not limited to, $-\text{OS}(=\text{O})\text{CH}_3$ and $-\text{OS}(=\text{O})\text{CH}_2\text{CH}_3$.

Sulfonyloxy: $-\text{OS}(=\text{O})_2\text{R}$, wherein R is a sulfonyloxy substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a
10 C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of sulfonyloxy groups include, but are not limited to, $-\text{OS}(=\text{O})_2\text{CH}_3$ (mesylate) and $-\text{OS}(=\text{O})_2\text{CH}_2\text{CH}_3$ (esylate).

Sulfate: $-\text{OS}(=\text{O})_2\text{OR}$; wherein R is a sulfate substituent, for
15 example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of sulfate groups include, but are not limited to, $-\text{OS}(=\text{O})_2\text{OCH}_3$ and $-\text{SO}(=\text{O})_2\text{OCH}_2\text{CH}_3$.

20 Sulfamyl (sulfamoyl; sulfinic acid amide; sulfinamide):
 $-\text{S}(=\text{O})\text{NR}^1\text{R}^2$, wherein R^1 and R^2 are independently amino substituents, as defined for amino groups. Examples of sulfamyl groups include, but are not limited to, $-\text{S}(=\text{O})\text{NH}_2$, $-\text{S}(=\text{O})\text{NH}(\text{CH}_3)$,
 $-\text{S}(=\text{O})\text{N}(\text{CH}_3)_2$, $-\text{S}(=\text{O})\text{NH}(\text{CH}_2\text{CH}_3)$, $-\text{S}(=\text{O})\text{N}(\text{CH}_2\text{CH}_3)_2$, and $-\text{S}(=\text{O})\text{NHPh}$.

25 Sulfonamido (sulfinamoyl; sulfonic acid amide; sulfonamide):
 $-\text{S}(=\text{O})_2\text{NR}^1\text{R}^2$, wherein R^1 and R^2 are independently amino substituents, as defined for amino groups. Examples of sulfonamido groups include, but are not limited to, $-\text{S}(=\text{O})_2\text{NH}_2$,
30 $-\text{S}(=\text{O})_2\text{NH}(\text{CH}_3)$, $-\text{S}(=\text{O})_2\text{N}(\text{CH}_3)_2$, $-\text{S}(=\text{O})_2\text{NH}(\text{CH}_2\text{CH}_3)$, $-\text{S}(=\text{O})_2\text{N}(\text{CH}_2\text{CH}_3)_2$, and $-\text{S}(=\text{O})_2\text{NHPh}$.

Sulfamino: $-\text{NR}^1\text{S}(=\text{O})_2\text{OH}$, wherein R^1 is an amino substituent, as defined for amino groups. Examples of sulfamino groups include,
35 but are not limited to, $-\text{NHS}(=\text{O})_2\text{OH}$ and $-\text{N}(\text{CH}_3)\text{S}(=\text{O})_2\text{OH}$.

Sulfonamino: $-\text{NR}^1\text{S}(=\text{O})_2\text{R}$, wherein R^1 is an amino substituent, as defined for amino groups, and R is a sulfonamino substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of
5 sulfonamino groups include, but are not limited to, $-\text{NHS}(=\text{O})_2\text{CH}_3$ and $-\text{N}(\text{CH}_3)\text{S}(=\text{O})_2\text{C}_6\text{H}_5$.

Sulfinamino: $-\text{NR}^1\text{S}(=\text{O})\text{R}$, wherein R^1 is an amino substituent, as defined for amino groups, and R is a sulfinamino substituent, for
10 example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of sulfinamino groups include, but are not limited to, $-\text{NHS}(=\text{O})\text{CH}_3$ and $-\text{N}(\text{CH}_3)\text{S}(=\text{O})\text{C}_6\text{H}_5$.

15 Phosphino (phosphine): $-\text{PR}_2$, wherein R is a phosphino substituent, for example, $-\text{H}$, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably $-\text{H}$, a C_{1-7} alkyl group, or a C_{5-20} aryl group. Examples of phosphino groups include, but are not limited to, $-\text{PH}_2$, $-\text{P}(\text{CH}_3)_2$, $-\text{P}(\text{CH}_2\text{CH}_3)_2$, $-\text{P}(\text{t-Bu})_2$, and $-\text{P}(\text{Ph})_2$.
20

Phospho: $-\text{P}(=\text{O})_2$.

Phosphinyl (phosphine oxide): $-\text{P}(=\text{O})\text{R}_2$, wherein R is a phosphinyl
25 substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group or a C_{5-20} aryl group. Examples of phosphinyl groups include, but are not limited to, $-\text{P}(=\text{O})(\text{CH}_3)_2$, $-\text{P}(=\text{O})(\text{CH}_2\text{CH}_3)_2$, $-\text{P}(=\text{O})(\text{t-Bu})_2$, and $-\text{P}(=\text{O})(\text{Ph})_2$.
30

Phosphonic acid (phosphono): $-\text{P}(=\text{O})(\text{OH})_2$.

Phosphonate (phosphono ester): $-\text{P}(=\text{O})(\text{OR})_2$, where R is a
35 phosphonate substituent, for example, $-\text{H}$, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably $-\text{H}$, a C_{1-7} alkyl group, or a C_{5-20} aryl group. Examples of phosphonate groups

include, but are not limited to, $-P(=O)(OCH_3)_2$, $-P(=O)(OCH_2CH_3)_2$, $-P(=O)(O-t-Bu)_2$, and $-P(=O)(OPh)_2$.

Phosphoric acid (phosphonooxy): $-OP(=O)(OH)_2$.

5

Phosphate (phosphonooxy ester): $-OP(=O)(OR)_2$, where R is a phosphate substituent, for example, -H, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably -H, a C_{1-7} alkyl group, or a C_{5-20} aryl group. Examples of phosphate groups
10 include, but are not limited to, $-OP(=O)(OCH_3)_2$, $-OP(=O)(OCH_2CH_3)_2$, $-OP(=O)(O-t-Bu)_2$, and $-OP(=O)(OPh)_2$.

Phosphorous acid: $-OP(OH)_2$.

15 Phosphite: $-OP(OR)_2$, where R is a phosphite substituent, for example, -H, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably -H, a C_{1-7} alkyl group, or a C_{5-20} aryl group. Examples of phosphite groups include, but are not limited to, $-OP(OCH_3)_2$, $-OP(OCH_2CH_3)_2$, $-OP(O-t-Bu)_2$, and $-OP(OPh)_2$.

20

Phosphoramidite: $-OP(OR^1)NR^2_2$, where R^1 and R^2 are phosphoramidite substituents, for example, -H, a (optionally substituted) C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably -H, a C_{1-7} alkyl group, or a C_{5-20} aryl group. Examples
25 of phosphoramidite groups include, but are not limited to, $-OP(OCH_2CH_3)N(CH_3)_2$, $-OP(OCH_2CH_3)N(i-Pr)_2$, and $-OP(OCH_2CH_2CN)N(i-Pr)_2$.

Phosphoramidate: $-OP(=O)(OR^1)NR^2_2$, where R^1 and R^2 are

30

phosphoramidate substituents, for example, -H, a (optionally substituted) C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably -H, a C_{1-7} alkyl group, or a C_{5-20} aryl group. Examples of phosphoramidate groups include, but are not limited to, $-OP(=O)(OCH_2CH_3)N(CH_3)_2$, $-OP(=O)(OCH_2CH_3)N(i-Pr)_2$, and
35 $-OP(=O)(OCH_2CH_2CN)N(i-Pr)_2$.

Gene-based diseases

Gene-based diseases include, and are preferably, proliferative diseases, and also include Alzheimer's disease and bacterial, parasitic and viral infections. Any condition which may be treated by the regulation of gene expression may be treated the compounds of the present invention.

Infection by gram-positive bacteria, and especially, MRSA and VRE, are particular preferred gene-based diseases in the present invention.

Proliferative Diseases

One of ordinary skill in the art is readily able to determine whether or not a candidate compound treats a proliferative condition for any particular cell type. For example, assays which may conveniently be used to assess the activity offered by a particular compound are described in the examples below.

The term "proliferative disease" pertains to an unwanted or uncontrolled cellular proliferation of excessive or abnormal cells which is undesired, such as, neoplastic or hyperplastic growth, whether *in vitro* or *in vivo*.

Examples of proliferative conditions include, but are not limited to, benign, pre-malignant, and malignant cellular proliferation, including but not limited to, neoplasms and tumours (e.g. histocytoma, glioma, astrocytoma, osteoma), cancers (e.g. lung cancer, small cell lung cancer, gastrointestinal cancer, bowel cancer, colon cancer, breast carcinoma, ovarian carcinoma, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreas cancer, brain cancer, sarcoma, osteosarcoma, Kaposi's sarcoma, melanoma), leukemias, psoriasis, bone diseases, fibroproliferative disorders (e.g. of connective tissues), and atherosclerosis.

Any type of cell may be treated, including but not limited to, lung, gastrointestinal (including, e.g. bowel, colon), breast (mammary), ovarian, prostate, liver (hepatic), kidney (renal), bladder, pancreas, brain, and skin.

5

Infection by gram-positive bacteria

Gram-positive bacteria have been discussed above. The treatment of methicillin resistant *Staphylococcus aureus* (MRSA) and vancomycin resistant enterococci (VRE) are of particular
10 interest, but the treatment of infection by other gram-positive bacteria, such as *Streptococcus pyogenes*, *Streptococcus agalactiae* and *Listeria monocytogenes* are also of interest.

Methods of Treatment

15 As described above, the present invention provides the use of a compound of formula I in a method of therapy. Preferably the compounds of formula I for use in therapy comprise two N10-C11 imine bonds, or the N10s are protected by nitrogen protecting groups (R^{10} , $R^{10'}$) which can be removed in vivo and the C11
20 substituents (R^{11} , $R^{11'}$) are OH. Also provided is a method of treatment, comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound of formula I, preferably in the form of a pharmaceutical composition, which is the third aspect of the present invention.
25 The term "therapeutically effective amount" is an amount sufficient to show benefit to a patient. Such benefit may be at least amelioration of at least one symptom. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated.
30 Prescription of treatment, e.g. decisions on dosage, is within the responsibility of general practitioners and other medical doctors.

A compound may be administered alone or in combination with other
35 treatments, either simultaneously or sequentially dependent upon the condition to be treated. Examples of treatments and therapies include, but are not limited to, chemotherapy (the

administration of active agents, including, e.g. drugs; surgery; and radiation therapy. If the compound of formula I bears a carbamate-based nitrogen protecting group which may be removed *in vivo*, then the methods of treatment described in WO 00/12507 (ADEPT, GDEPT and PDT) may be used.

Pharmaceutical compositions according to the present invention, and for use in accordance with the present invention, may comprise, in addition to the active ingredient, i.e. a compound of formula I, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material will depend on the route of administration, which may be oral, or by injection, e.g. cutaneous, subcutaneous, or intravenous.

Pharmaceutical compositions for oral administration may be in tablet, capsule, powder or liquid form. A tablet may comprise a solid carrier or an adjuvant. Liquid pharmaceutical compositions generally comprise a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included. A capsule may comprise a solid carrier such as a gelatin.

For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.


Includes Other Forms

Unless otherwise specified, included in the above are the well known ionic, salt, solvate, and protected forms of these substituents. For example, a reference to carboxylic acid (-COOH) also includes the anionic (carboxylate) form (-COO⁻), a salt or solvate thereof, as well as conventional protected forms. Similarly, a reference to an amino group includes the protonated form (-N⁺HR¹R²), a salt or solvate of the amino group, for example, a hydrochloride salt, as well as conventional protected forms of an amino group. Similarly, a reference to a hydroxyl group also includes the anionic form (-O⁻), a salt or solvate thereof, as well as conventional protected forms.

Isomers, Salts and Solvates

Certain compounds may exist in one or more particular geometric, optical, enantiomeric, diastereomeric, epimeric, atropic, stereoisomeric, tautomeric, conformational, or anomeric forms, including but not limited to, cis- and trans-forms; E- and Z-forms; c-, t-, and r- forms; endo- and exo-forms; R-, S-, and meso-forms; D- and L-forms; d- and l-forms; (+) and (-) forms; keto-, enol-, and enolate-forms; syn- and anti-forms; synclinal- and anticlinal-forms; α- and β-forms; axial and equatorial forms; boat-, chair-, twist-, envelope-, and halfchair-forms; and combinations thereof, hereinafter collectively referred to as "isomers" (or "isomeric forms").


Preferably compounds of the present invention have the following stereochemistry at the C11 position:



Note that, except as discussed below for tautomeric forms, specifically excluded from the term "isomers", as used herein, are structural (or constitutional) isomers (i.e. isomers which

differ in the connections between atoms rather than merely by the position of atoms in space). For example, a reference to a methoxy group, $-\text{OCH}_3$, is not to be construed as a reference to its structural isomer, a hydroxymethyl group, $-\text{CH}_2\text{OH}$. Similarly, a reference to ortho-chlorophenyl is not to be construed as a reference to its structural isomer, meta-chlorophenyl. However, a reference to a class of structures may well include structurally isomeric forms falling within that class (e.g. C_{1-7} alkyl includes n-propyl and iso-propyl; butyl includes n-, iso-, sec-, and tert-butyl; methoxyphenyl includes ortho-, meta-, and para-methoxyphenyl).

The above exclusion does not pertain to tautomeric forms, for example, keto-, enol-, and enolate-forms, as in, for example, the following tautomeric pairs: keto/enol (illustrated below), imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime, thioketone/enethiol, N-nitroso/hydroxyazo, and nitro/aci-nitro.



Note that specifically included in the term "isomer" are compounds with one or more isotopic substitutions. For example, H may be in any isotopic form, including ^1H , ^2H (D), and ^3H (T); C may be in any isotopic form, including ^{12}C , ^{13}C , and ^{14}C ; O may be in any isotopic form, including ^{16}O and ^{18}O ; and the like.

Unless otherwise specified, a reference to a particular compound includes all such isomeric forms, including (wholly or partially) racemic and other mixtures thereof. Methods for the preparation (e.g. asymmetric synthesis) and separation (e.g. fractional crystallisation and chromatographic means) of such isomeric forms are either known in the art or are readily obtained by adapting the methods taught herein, or known methods, in a known manner.

Unless otherwise specified, a reference to a particular compound also includes ionic, salt, solvate, and protected forms of thereof, for example, as discussed below.

5 It may be convenient or desirable to prepare, purify, and/or handle a corresponding salt of the active compound, for example, a pharmaceutically-acceptable salt. Examples of pharmaceutically acceptable salts are discussed in Berge, *et al.*, *J. Pharm. Sci.*, 66, 1-19 (1977).

10

For example, if the compound is anionic, or has a functional group which may be anionic (e.g. $-\text{COOH}$ may be $-\text{COO}^-$), then a salt may be formed with a suitable cation. Examples of suitable inorganic cations include, but are not limited to, alkali metal ions such as Na^+ and K^+ , alkaline earth cations such as Ca^{2+} and Mg^{2+} , and other cations such as Al^{+3} . Examples of suitable organic cations include, but are not limited to, ammonium ion (i.e. NH_4^+) and substituted ammonium ions (e.g. NH_3R^+ , NH_2R_2^+ , NHR_3^+ , NR_4^+). Examples of some suitable substituted ammonium ions are those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine. An example of a common quaternary ammonium ion is $\text{N}(\text{CH}_3)_4^+$.

20

25

If the compound is cationic, or has a functional group which may be cationic (e.g. $-\text{NH}_2$ may be $-\text{NH}_3^+$), then a salt may be formed with a suitable anion. Examples of suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and phosphorous.


30

35

Examples of suitable organic anions include, but are not limited to, those derived from the following organic acids: 2-acetoxybenzoic, acetic, ascorbic, aspartic, benzoic, camphorsulfonic, cinnamic, citric, edetic, ethanedisulfonic,

ethanesulfonic, fumaric, glucheptonic, gluconic, glutamic, glycolic, hydroxymaleic, hydroxynaphthalene carboxylic, isethionic, lactic, lactobionic, lauric, maleic, malic, methanesulfonic, mucic, oleic, oxalic, palmitic, pamoic, pantothenic, phenylacetic, phenylsulfonic, propionic, pyruvic, salicylic, stearic, succinic, sulfanilic, tartaric, toluenesulfonic, and valeric. Examples of suitable polymeric organic anions include, but are not limited to, those derived from the following polymeric acids: tannic acid, carboxymethyl cellulose.

A particular salt form of interest can be formed from compounds of formula I, where R^{10} and R^{11} (and/or $R^{10'}$ and $R^{11'}$) form an imine bond, by reacting said compound with a bisulphite salt to form a bisulphite derivative of the PBD. These compounds can be represented as:




where M is a monovalent pharmaceutically acceptable cation, or if both PBDs are of these form, both Ms together form may a divalent pharmaceutically acceptable cation..

It may be convenient or desirable to prepare, purify, and/or handle a corresponding solvate of the active compound. The term "solvate" is used herein in the conventional sense to refer to a complex of solute (e.g. active compound, salt of active compound) and solvent. If the solvent is water, the solvate may be conveniently referred to as a hydrate, for example, a mono-hydrate, a di-hydrate, a tri-hydrate, etc.

Solvates of particular relevance to the present invention are those where the solvent adds across the imine bond of the PBD, which is illustrated below where the solvent is water or an

alcohol ($R^A\text{OH}$, where R^A is an ether substituent as described above):



wherein, * indicates the dimer bridge ($-\text{O}-(\text{CH}_2)_5-\text{O}-$) to the corresponding PBD unit.

These forms can be called the carbinolamine and carbinolamine ether forms of the PBD. The balance of these equilibria depend on the conditions in which the compounds are found, as well as the nature of the moiety itself.

In general any nucleophilic solvent is capable of forming such solvates as illustrated above for hydroxylic solvents. Other nucleophilic solvents include thiols and amines.

These solvates may be isolated in solid form, for example, by lyophilisation.

Brief Description of Figures

Figure 1 shows the distribution of MICs of different MRSA strains for compound 1;

Figure 2 shows the distribution of MICs of different VRE strains for compound 1;


Figures 3a and 3b show the antibacterial activity of compound 1 on MRSA strain P1 at different time points, where the bacterial counts were calculated from 20 μL drops and 100 μL drops of the bacterial suspensions respectively.

General synthetic routes

The compounds of formula I may be made by two alternative routes which are similar to those described in WO 00/12508. An important step is the formation of the C2-exo double bond. This

may proceed by the methods described in schemes 8 and 9 of WO 00/12508.

One method involves the synthesis of the compound to provide the C-ring before coupling to the remainder of the molecule.




Scheme 1

Commercially available trans-4-hydroxy-L-proline **A** can be N-alloc protected (or with any other suitable nitrogen protecting group) to give the protected compound **B** which can then be esterified using standard conditions. Hydride reduction of the ester **C** furnishes the diol **D**. Selective TBDMS protection of the diol gives a silyl ether **E**, which can then be oxidised, using, for example, Swern or TPAP oxidation, to provide the ketone **F**.

The C2-ethylidene functionality may be introduced by performing the Wittig reaction on ketone **F**. Palladium-mediated cleavage of the N-alloc protecting group yields compound **H**.


The compound H may then be joined to the A-ring dimer as follows:



Scheme 2

As shown in Scheme 2, the compound **H** is coupled (in 2 equivalents) to the N-troc protected anthranilic acid dimer **I**,
5 where * indicates the dimer bridge (-O-(CH₂)₅-O-) to the corresponding PBD unit. This coupling is followed by deprotection of the alcohol to provide compound **K**.


The alternative approach to compound **K** involves similar steps,
10 but in a different order, as shown in scheme 3:



Scheme 3

The nitro dimer **M** is synthesised by coupling the amine **E'** to the dimeric acid chloride **L**. The nitro dimer is then converted to the protected aniline **O** via the aniline **N**, by reduction and then protection. The hydroxy group in the C ring can then be converted to the ketone (**P**) and subsequently ethylidene (**Q**) as described above. The compound **Q** may then be deprotected on the hydroxy to yield compound **K**.

The compound **K** may then be cyclised to yield a compound of formula **I**, wherein R¹¹ is OH:



Exposure of the alcohol **K** (in which the Pro-N10-nitrogen is protected as carbamate) to tetrapropylammonium perruthenate (TPAP)/N-methylmorpholine N-oxide (NMO) over A4 sieves results in oxidation accompanied by spontaneous B-ring closure to afford the desired product. The TPAP/NMO oxidation procedure is found to be particularly convenient for small scale reactions while the use of DMSO-based oxidation methods, particularly Swern oxidation, proves superior for larger scale work (e.g. > 1 g). A particularly preferred oxidising agent is (diacetoxyiodo)benzene (1.1 eq) and TEMPO (0.1 eq) dissolved in CH₂Cl₂.

Alternative methods of cyclisation are illustrated in WO 00/12508.

The compound of formula **I** where R¹⁰ is a nitrogen protecting group and R¹¹ is OH may be deprotected to a compound with N10-C11 imine bonds, by removal of the nitrogen protecting groups using appropriate conditions. If in the compound of formula **I**, R¹¹ is O-R¹², then the oxygen protecting group can be introduced using the appropriate conditions.

The relative amounts of different forms of the compound of formula **I** with regard to the geometry of the C2-exo double bond may be affected by the synthesis route used, and, in particular, by the Wittig reagent used.

Further preferences

It is preferred that R¹⁰ and R¹¹ together form a double bond between N10 and C11.

- 5 It is preferred that the compound of formula I comprises at least 50% in either the E-, E- or Z-, Z- forms, with more preferably at least 70%, 80%, 90% or 95% in one of these forms. The Z-, Z- form is preferred.

10 **Examples**

General Methods


- Progress of reaction was monitored by thin-layer chromatography (TLC) using GF254 silica gel, with fluorescent indicator on glass plates. Visualization of TLC plates was achieved with UV light
15 and I₂ vapour unless otherwise stated. Flash chromatography was performed using silica gel (14 cm column of J.T Baker 30-60 μm). The majority of reaction solvents were purified and used fresh by distillation under nitrogen from the indicated drying agent: CH₂Cl₂ and MeCN (CaH₂), tetrahydrofuran and toluene (sodium
20 benzophenone ketyl), and MeOH (magnesium turnings and catalytic iodine). Extraction and chromatography solvents were purchased and used without further purification from J.T Baker. All organic chemicals were purchased from Aldrich Chemical Co. Drying agents and inorganic reagents were bought from BDH.

- 25 IR spectra were recorded with a Perkin-Elmer FT/IR-Paragon 1000 spectrophotometer. ¹H and ¹³C NMR spectra were obtained on a Jeol GSX 270 MHz (67.8 MHz for ¹³C NMR spectra), Brüker ARX 250 MHz (62.9 MHz for ¹³C NMR spectra) or Jeol JNM-LA 400 MHz (100 MHz for
30 ¹³C NMR spectra) FT-NMR instrument operating at 20 °C±1 °C.

- Chemical shifts are reported in parts per million (δ ppm) downfield from internal Me₄Si. Spin multiplicities are described as s (singlet), br s (broad singlet), d (doublet), br d (broad doublet), t (triplet), q (quartet), quint (quintet) and m
35 (multiplet). Mass spectra were recorded on a Jeol JMS-DX 303 GC-mass spectrometer or a VG ZAB-SE double-focusing instrument.

Electron impact (EI) mass spectra were obtained at 70 eV, chemical ionisation (CI) spectra were obtained using isobutane as reagent gas, and fast atom bombardment (FAB) spectra were recorded using 3-nitrobenzyl alcohol as a matrix with Xe reagent gas. Accurate molecular masses were determined by peak matching using perfluorokerosene (PFK) as an internal standard. Optical rotations were measured at ambient temperature using a Bellingham and Stanley ADP 220 polarimeter.

Example 1 - Synthesis of 1,1'-[(Pentane-1,5-diyl)dioxy]-bis[(11aS,2Z)-7-methoxy-2-ethylidene-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one] (1)



(a) 1,1'-[[(Pentane-1,5-diyl) dioxy]-bis[2-amino-N-allyloxycarbonyl-5-methoxy-1,4-phenylenecarbonyl]]-bis[(2S,4Z)-2-t-butyl dimethylsilyloxymethyl-4-ethylidene-2,3-dihydropyrrole] (3)

A solution of potassium-*t*-butoxide in dry THF (0.5 M, 21.0 mL, 10.6 mmol) was added dropwise to a suspension of ethyltriphenylphosphonium bromide (3.94 g, 10.6 mmol) in dry THF (16 mL). The resulting yellow ylide suspension was allowed to stir at reflux for 2 hours before the addition of a solution of the bis-ketone 2 (Compound 214 from WO 00/12508) (2.09 g, 2.04 mmol) in THF (15 mL) at 10°C. The reaction mixture was allowed to stir at reflux for a further 90 minutes and then allowed to

cool to room temperature. The mixture was partitioned between EtOAc (100 mL) and water (100 mL) and the organic layer was washed with sat. sodium chloride (100 mL) and dried over MgSO₄. Removal of excess solvent gave a brown oil that was subjected to

5 flash column chromatography (50:50 v/v EtOAc/40-60° petroleum ether) to afford the olefin **3** as a yellow glass. Yield = 577 mg (28%); $[\alpha]_D^{24} = -26^\circ$ ($c = 0.453$, CHCl₃); ¹H NMR (250 MHz, CDCl₃) δ 8.82 (bs, 2H), 7.81 (bs, 2H), 6.84 (s, 2H), 6.02-5.87 (m, 2H), 5.38-5.20 (m, 6H), 4.63-4.55 (m, 6H), 4.15-3.85 (m, 8H), 3.82-

10 3.52 (m, 10H), 2.75-2.49 (m, 4H), 2.03-1.80 (m, 4H), 1.77-1.22 (m, 8H), 0.85 (s, 18H), 0.00 (s, 12H); ¹³C NMR (62.9 MHz, CDCl₃) δ 168.9, 153.5, 150.6, 143.9, 135.6, 132.6, 131.9, 118.0, 116.7, 115.4, 111.3, 105.4, 68.6, 65.7, 63.7, 56.6, 54.6, 33.4, 28.8, 25.8, 22.6, 18.1, 14.6, -5.58; MS (FAB) m/z (relative intensity)

15 1072 ($[M + Na + H]^+$, 65), 1049 ($[M + H]^+$, 28), 992 (13), 809 (39), 509 (33), 469 (49), 318 (26), 268 (100); IR (Neat) 3319 (br), 2952, 2930, 2858, 1732, 1600, 1524, 1470, 1407, 1360, 1331, 1258, 1202, 1115, 1052, 1027, 938, 837, 812, 666 cm⁻¹; HRMS $[M + Na]^+$ calcd for C₅₅H₈₄N₄O₁₂Si₂Na m/z 1071.5522, found (FAB) m/z

20 1071.5468.

(b) 1,1'-[[[(Pentane-1,5-diyl)dioxy]-bis[2-amino-N-allyloxycarbonyl-5-methoxy-1,4-phenylenecarbonyl]]-bis[(2S,4Z)-2-hydroxymethyl-4-ethylidene-2,3-dihydropyrrole] (**4**)

25 A solution of TBAF (3.00 mL of a 1.0 M solution in THF, 3.00 mmol) was added to the bis-silyl ether **3** (1.23 g, 1.21 mmol) in THF (30 mL) at 0°C (ice/acetone). The reaction mixture was allowed to warm to room temperature and to stir overnight, the following day, TLC (50:50 v/v EtOAc/40-60° petroleum ether)

30 revealed the complete disappearance of starting material. Saturated NH₄Cl (150 mL) was added and the reaction mixture extracted with EtOAc (3 x 60 mL), washed with sat. sodium chloride (150 mL), dried (MgSO₄), filtered and evaporated *in vacuo* to give a yellow oil. Purification by flash chromatography

35 (97:3 v/v CHCl₃/MeOH) provided the pure alcohol **4** as a white foam. Yield = 879 mg (91%); $[\alpha]_D^{23} = -2^\circ$ ($c = 0.29$, CHCl₃); ¹H NMR

(250 MHz, CDCl₃) δ 8.64 (bs, 2H), 7.58 (bs, 2H), 6.82 (bs, 2H), 6.04–5.88 (m, 2H), 5.41–5.21 (m, 6H), 4.71–4.56 (m, 6H), 4.12–3.60 (m, 20H), 2.72 (dd, 2H, J = 8.2, 15.1 Hz), 2.38 (d, 2H, J = 15.3 Hz), 2.00–1.89 (m, 4H), 1.75–1.50 (m, 8H); ¹³C NMR (62.9 MHz, CDCl₃) δ 170.5, 153.7, 150.4, 144.5, 134.2, 132.6, 130.9, 118.0 (x 2), 116.2, 110.9, 106.0, 68.5, 65.7, 65.3, 59.4, 56.6, 51.0, 34.1, 28.6, 22.7, 14.6; MS (FAB) m/z (relative intensity) 843 ([M + Na]⁺, 100), 821 ([M + H]⁺, 17), 694 (32), 509 (43), 469 (40), 421 (25), 336 (50), 307 (34); IR (CHCl₃) 3355 (br), 3016, 2941, 2875, 1723, 1600, 1525, 1465, 1434, 1409, 1330, 1266, 1216, 1179, 1118, 1072, 1051, 1028, 995, 933, 872, 667 cm⁻¹; HRMS [M + Na]⁺ calcd for C₄₃H₅₆N₄O₁₂Na m/z 843.3792, found (FAB) m/z 843.3823.

(c) 1,1'-[(Pentane-1,5-diyl)dioxy]-bis[(11*S*,11*aS*,2*Z*)-10-(allyloxycarbonyl)-11-hydroxy-7-methoxy-2-ethylidene-1,2,3,10,11,11*a*-hexahydro-5*H*-pyrrolo[2,1-*c*][1,4]benzodiazepin-5-one] (5)

A solution of dimethyl sulphoxide (0.45 g, 0.41 mL, 5.80 mmol) in dry CH₂Cl₂ (8 mL) was added dropwise, over a 15 minute period, to a stirred solution of oxalyl chloride (1.46 mL of a 2M solution in CH₂Cl₂, 2.92 mmol) at -45°C under a nitrogen atmosphere. The reaction mixture was allowed to stir for 35 minutes at -45°C followed by addition of the diol 4 (0.85 g, 1.04 mmol) in CH₂Cl₂ (8 mL) at the same temperature over 15 minutes. After a further 45 minutes a solution of triethylamine (0.83g, 1.14 mL, 8.20 mmol) in CH₂Cl₂ (8 mL) was added over a period of 15 minutes. The reaction mixture was allowed to stir at -45°C for 30 minutes before being allowed to warm to room temperature over 45 minutes. The reaction mixture was diluted with CH₂Cl₂ and was washed with 1M HCl (3 x 50 mL), brine (50 mL) and dried over MgSO₄. Removal of excess solvent yielded the crude product, which was purified by flash column chromatography (99:1 v/v CHCl₃/MeOH) to afford the product as a white glass 5. Yield = 0.495 g (58%); [α]_D²² = +168° (c = 0.28, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 7.23 (s, 2H), 6.66 (s, 2H), 5.90–5.70 (m, 2H), 5.59–5.40 (m, 4H), 5.16 (bs, 2H), 5.11 (bs, 2H), 4.66 (dd, 2H, J = 5.57, 13.59 Hz), 4.44 (d,

2H, $J = 13.2$ Hz), 4.29–4.07 (m, 6H), 4.01 (t, 4H, $J = 6.5$ Hz), 3.90 (s, 6H), 3.63–3.56 (m, 2H), 2.93–2.77 (m, 2H), 2.66 (d, 2H, $J = 16.4$ Hz), 1.97–1.86 (m, 4H), 1.68–1.61 (m, 8H); ^{13}C NMR (62.9 MHz, CDCl_3) δ 166.8, 155.9, 150.2, 148.8, 133.0, 131.8, 128.4, 125.5, 119.6, 118.2, 113.9, 110.6, 85.9, 69.0, 66.8, 59.3, 56.1, 47.5, 34.8, 28.5, 22.4, 14.8; MS (FAB) m/z (relative intensity) 839 ($[M + \text{Na}]^+$, 100), 799 (10), 781 (14), 465 (14), 443 (16), 413 (37), 388 (19), 336 (25), 271 (25); IR (CHCl_3) 3225 (br), 3011, 2938, 2860, 1704, 1605, 1515, 1469, 1436, 1410, 1307, 1284, 1215, 1129, 1077, 1018, 994, 959, 916, 872, 666, 637 cm^{-1} ; HRMS $[M + \text{Na}]^+$ calcd for $\text{C}_{43}\text{H}_{52}\text{N}_4\text{O}_{12}\text{Na}$ m/z 839.3479, found (FAB) m/z 839.3497.


(d) 1,1'-[(Pentane-1,5-diyl)dioxy]-bis[(11aS,2Z)-7-methoxy-2-ethylidene-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one] (**1**)

A catalytic amount of tetrakis(triphenylphosphine)palladium (14.4 mg, 12.5 μmol) was added to a stirred solution of the bis-alloc-carbinolamine **5** (200 mg, 0.25 mmol), triphenylphosphine (6.30 mg, 24.1 μmol) and pyrrolidine (33 mg, 40.1 μL 0.48 mmol) in CH_2Cl_2 (13 mL) under a nitrogen atmosphere. The reaction mixture was allowed to warm to room temperature and the progress of reaction monitored by TLC (95:5 v/v $\text{CHCl}_3/\text{MeOH}$). After two and a half hours TLC revealed the reaction was complete to give a spot which fluoresced brightly under UV light. The solvent was evaporated under reduced pressure and the resulting residue subjected to flash chromatography (98:2 v/v $\text{CHCl}_3/\text{MeOH}$) to give the bis-imine target molecule **1** as a pale orange glass which was repeatedly evaporated *in vacuo* with CHCl_3 to provide the imine form. Yield = 160 mg (Quant); $[\alpha]_D^{21} = +937^\circ$ ($c = 0.641$, CHCl_3); ^1H NMR (250 MHz, CDCl_3) δ 7.67 (d, 2H, $J = 4.5$ Hz), 7.50 (s, 2H), 6.80 (s, 2H), 5.63–5.55 (m, 2H), 4.38–3.96 (m, 8H), 3.94 (s, 6H), 3.86–3.80 (m, 2H), 3.20–3.03 (m, 2H), 2.90 (d, 2H, $J = 15.8$ Hz), 2.00–1.91 (m, 4H), 1.76–1.68 (m, 8H); ^{13}C NMR (62.9 MHz, CDCl_3) δ 164.9, 163.0, 150.8, 147.8, 140.6, 132.9, 119.8, 119.3, 111.4, 110.3, 68.7, 56.1, 53.4, 48.3, 35.3, 28.6, 22.5, 14.9; MS (FAB)


m/z (relative intensity) 613 ($[M + H]^+$, 52), 443 (26), 421 (22), 329 (100), 307 (71), 242 (35), 220 (38); IR (CHCl_3) 3220 (br), 2940, 2859, 1697, 1602, 1560, 1508, 1458, 1432, 1382, 1341, 1263, 1217, 1132, 1098, 1065, 1007, 875, 666 cm^{-1} ; HRMS $[M + H]^+$ calcd for $\text{C}_{35}\text{H}_{41}\text{N}_4\text{O}_6$ m/z 613.3026, found (FAB) m/z 613.3047.

Determination of relative amounts of geometric isomers

The chemical shift differences observed in the ^{13}C NMR spectra for the C1 and C3 resonances of the E/Z ethylidene group of the PBD allows the determination of approximate geometric isomer ratios in compound **1**. These observations are based on work published on the total synthesis of the PBD natural products tomaymycin and prothracarcin which contain C2-ethylidene moieties (Mori, M., et al., *Tetrahedron*, **42**, 3793 (1986)).



E-prothracarcin



Z-prothracarcin

Table 1 shows a comparison of ^{13}C NMR signals for C1 and C3 of *E*- and *Z*-prothracarcin and *E/Z* forms of the C2-exo double bond of Compound **1**. The relative signal intensities measured for Compound **1** are quoted in parentheses.

	Chemical Shift (ppm)			
	<i>E</i> - prothracarcin	<i>Z</i> - prothracarcin	<i>E</i> -1	<i>Z</i> -1
C1	31.1	35.3	31.1 (0.21)	35.3 (2.60)
C3	51.6	48.3	51.6 (0.20)	48.3 (2.84)

Table 1

From these data the approximate amount of C2 exo double bond in the *Z*- form is 93.6% and in the *E*- form is 6.4% which give the relative amounts of geometric isomers of compound 1 as below:

Geometric isomers at C2/C2'	Amount (%)
<i>E</i> -, <i>E</i> -	0.4
<i>E</i> -, <i>Z</i> -	12
<i>Z</i> -, <i>Z</i> -	87.6

In addition, NOESY (through space correlations) spectra on compound 1 supports the structural assignment.

Example 2 - Biological Evaluation

K562 Assay

K562 human chronic myeloid leukaemia cells were maintained in RPM1 1640 medium supplemented with 10% fetal calf serum and 2 mM glutamine at 37°C in a humidified atmosphere containing 5% CO₂ and were incubated with a specified dose of the test compound for 1 hour at 37°C in the dark. The incubation was terminated by centrifugation (5 minutes, 300 g) and the cells were washed once with drug-free medium. Following the appropriate drug treatment, the cells were transferred to 96-well microtiter plates (10⁴ cells per well, 8 wells per sample). Plates were then kept in the dark at 37°C in a humidified atmosphere containing 5% CO₂.

The assay is based on the ability of viable cells to reduce a yellow soluble tetrazolium salt, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT, Aldrich-Sigma), to an insoluble purple formazan precipitate. Following incubation of the plates for 4 days (to allow control cells to increase in number by approximately 10 fold), 20 μ L of MTT solution (5 mg/mL in phosphate-buffered saline) was added to each well and the plates further incubated for 5 hours. The plates were then centrifuged for 5 minutes at 300 g and the bulk of the medium pipetted from the cell pellet leaving 10-20 μ L per well. DMSO (200 μ L) was added to each well and the samples agitated to ensure complete mixing. The optical density was then read at a wavelength of 550 nm on a Titertek Multiscan ELISA plate reader, and a dose-response curve was constructed. For each curve, an IC_{50} value was read as the dose required to reduce the final optical density to 50% of the control value.

The IC_{50} value measured for compound 1 was >0.05 nM, which compares to a value for the compound of Example 6 in WO 93/18045 quoted as 10 nM.

DNA Cross-linking Assay

The extent of DNA cross-linking induced by the test compound was determined using the electrophoretic assay method of Hartley and co-workers (Hartley, J. A., et al., *Analytical Biochemistry*, **193**, 131-134 (1991)). Closed-circular puc18 DNA was linearized with HindIII, then dephosphorylated and finally 5'-singly end-labelled using [γ^{32} P]-ATP and polynucleotide kinase. Reactions containing 30-40 ng of DNA were carried out in aqueous TEOA (25 mM triethanolamine, 1 mM EDTA, pH 7.2) buffer at 37°C in a final volume of 50 μ L. Reactions were terminated by addition of an equal volume of stop solution (0.6 M NaOAc, 20 mM EDTA, 100 μ g/mL tRNA) followed by precipitation with EtOH. Following centrifugation, the supernatant was discarded and the pellet dried by lyophilization. Samples were re-suspended in 10 μ L of strand separation buffer (30% DMSO, 1 mM EDTA, 0.04% bromophenol blue

and 0.04% xylene cyanol) and denatured by heating to 90°C for 2.5 minutes, followed by immersion in an ice/water bath. Control, non-denatured, samples were re-suspended in 10 µL of non-denaturing buffer solution (0.6% sucrose, 0.04% bromophenol blue in aqueous TAE buffer [40 mM Tris, 20 mM acetic acid, 2 mM EDTA, pH 8.1]) and loaded directly onto the gel for comparison. Electrophoresis was carried out for 14-16 h at 40 V using a 0.8% submerged agarose gel (20 × 25 × 0.5 cm) in TAE buffer. Gels were dried under vacuum for 2 hours at 80°C onto one layer each of Whatman 3MM and DE8I filter papers using a BioRad 583 gel dryer. Autoradiographs were obtained after exposure of Hyperfilm-MP film (Amersham plc, U.K.) to the dried gel for either 4 h with a screen, or overnight without a screen (to obtain a sharper image). Film bands were quantitated using a BioRad GS-670 imaging laser densitometer. Percentage cross-linking was calculated by measuring the total DNA in each lane (summed density for the double-stranded [DS] and single-stranded [SS] bands) relative to the amount of cross-linked DNA (density of DS band alone). A dose-response curve was derived by plotting drug concentration against the determined percentage level of cross-linked DNA, and the result XL_{50} determined as the amount required to cross-link 50%.

The XL_{50} determined for compound **1** was 2.7 ± 1.6 nM.

Example 3 - Antibacterial Evaluation

Materials and Methods

Collections

The MRSA collection held by Dr P. Taylor, School of Pharmacy, London (UK) was used to evaluate compound **1**. It comprises 38 strains includes many international strains, as the epidemic EMRSA-15 and EMRSA-16, responsible in many outbreaks in UK hospitals for the last decade. The countries of origin of these strains is shown in table 2.

Table 2

Country of Origin	Strain No.
Australia	Aus K, Aus D, Aus 5, Aus 7
Brazil	BZ16, BZ23, BZ24, BZ9, BZ20
Chile	Chil 1
Denmark	DEN 2, DEN 3
France	F2, F4, F25
Finland	FIN 12, FIN 10
Germany	G13, G1, G2, G3, G14, EG6
Greece	AT5, AT6
Hong Kong	HK 1
India	Ind3
Israel	IS 1
Poland	POL2, POL3
Portugal	P1, P3
Kuwait	KW7
South Carolina	SC4
Turkey	T7
United Kingdom	EMRSA15, EMRSA16

VRE and the remaining strains used are also held by Dr P. Taylor and are from UK collections. The following number of clinical isolates were used - 20 VRE, 12 *Streptococcus pyogenes*, 12 *Streptococcus agalactiae*, 12 *Listeria monocytogenes*.

MICs (Maximum Inhibitory Concentrations)

Broth MICs were performed according to the method given by the National Committee for Clinical Laboratory Standards, UK (NCCLS) guidelines. 100 µl of the compound to be tested, suspended in Muller Hinton Broth (MHB), was dispensed in a sterile 96 well microtitre plate at the desired concentrations. One row of wells contained only 100µl of MHB, without compound, to be used as a control. Bacterial cultures grown overnight in 2ml of MHB were diluted down, prior to adding 100 µl of each sample to the wells, in order to obtain a final bacterial count of 5×10^5 CFU/ml, i.e.

10⁵ CFU per well. A final volume of 200 µl per well was obtained. A 1 in 2 dilution of the bacterial sample, achieved once the sample was added to the well, must be taken into consideration when calculating the final bacterial count. An adhesive plastic seal
5 was used to seal off the microtitre plate, which was then gently shaken in order to suspend the bacterial samples evenly. The plate was incubated overnight at 37°C. The lowest concentration at which there was no visible growth of bacteria is defined as the MIC for that particular bacterial strain.

10

The test was valid if there was evidence of bacterial growth in the control set of wells. Bacterial growth is usually represented by buttons or clumps at the bottom of the well, however some wells may appear turbid. A clear well indicates
15 inhibition of growth.

The average count of Gram-positive bacterial culture was 10⁹ bacteria/ml which was taken into consideration when bacterial dilutions were performed prior to proceeding with the MIC test.
20 Viable counts from the diluted bacterial suspensions were performed in order to confirm that the right final bacterial count has been achieved.

Antimicrobial susceptibility tests

25 These were performed in accordance with the NCCLS guidelines, Sixth edition, Jan 1997.

Several bacterial colonies were transferred from the agar plates to bijoux containing MHB. The suspension is incubated at 35°C
30 and subsequently diluted down in sterile saline to match the density of a McFarland standard solution. A sterile cotton swab is then dipped in the bacterial inoculum and pressed against the bijou walls to remove any excess solution. MHA plates are then thoroughly streaked with the swab three times, turning the plate
35 60° each time. The discs are placed onto the inoculated plate within 15 minutes. The positions of the discs should allow

enough space ($\approx 24\text{mm}$) around each individual disc in order to measure the diffusion diameter at a later stage. The plates were incubated immediately at 35°C for 16-18 hours for all organisms excluding VRE, and MRSA, which require a 24-hour incubation. The experiment was valid if there was a confluent bacterial growth, not single colonies, and circular inhibition zones were evident. Clear zones produced around the disc were measured with a ruler and interpreted according to the tables provided by the NCCLS. Bacteria were classified as sensitive, intermediate or resistant.

Time-kill studies

250ml flasks containing 50ml of MHB were sterilised. One was kept as control, while the compound to be tested was added to the remaining three in an increasing concentration as follows: MICx1, MICx2 and MICx4. An overnight bacterial culture was diluted one in two. 50 ml of that suspension were added to each flask and the time noted as time 0. Samples of each flask were taken out immediately and dispensed in bijoux bottles. 100 μl of each sample were transferred to 900 μl of sterile PBS. Further 10-fold dilutions were carried out as necessary. 20 μl drops of each dilution were plated out onto NA plates and incubated overnight at 37°C . The flasks were left on a shaker at 37°C . The same procedure was repeated at time 1, 2, 4, 6 and 24h and plates were incubated overnight.

Bacterial colonies were counted the next day. Once it was established at what dilution, number of colonies was countable the experiment was repeated, however instead of plating out 20 μl drops, 100 μl of the corresponding dilutions were spread onto a whole plate using a sterile glass rod. This enables more accurate bacterial count of the primary suspension in the flask.

Results

MICs

The average MICs for compound 1 against the collections of bacteria tested are shown in Table 3.

5

Table 3

	MIC ₉₀ µg/ml (mg/L)
MRSA	0.03
VRE	0.06
<i>Streptococcus pyogenes</i>	0.015
<i>Streptococcus agalactiae</i>	0.015
<i>Listeria monocytogenes</i>	0.06

The MICs observed in MRSA against the recently introduced antibiotics linezolid and synercid are in the range of 1 mg/L and 0.5 mg/L respectively (Munoz Bellido, J.L., et al., *International Journal of Antimicrobial Agents*, **20**, 61-64 (2002); Abb, J., *Diagnostic Microbiology and Infectious Disease*, **43**, 319-321 (2002)). The MIC for vancomycin against MRSA is about 2 mg/L.

Figure 1 shows the distribution of MICs for the different strains of MRSA tested and Figure 2 shows the distribution of MICs for the different strains of VRE tested.

Antibiotic susceptibility testing

The bacteria used to assess the antibacterial activity of compound 1 were tested against a wide range of antibiotics to determine their overall susceptibility to other antimicrobial agents, and the results are shown in tables 4 to 8 below.

Table 4. MRSA susceptibility to current antibiotics.

	Resistant %	Sensitive %	Intermediate %
Oxacillin	100	–	–
Vancomycin	–	100	–
Trimethophrim	32	68	–
Amikacin	16	73	11
Gentamicin	70	22	8
Tetracycline	84	16	–
Rifampicin	11	81	8
Ciprofloxacin	11	89	–
Erythromycin	11	89	–
Clindamycin	41	59	–

Table 5. VRE susceptibility to current antibiotics.

	Resistant %	Sensitive %	Intermediate %
Oxacillin	100	–	–
Vancomycin	100	–	–
Trimethophrim	75	25	–
Amikacin			
Gentamicin	80	20	–
Tetracycline	60	40	–
Rifampicin			
Ciprofloxacin	50	20	30
Erythromycin	90	10	–
Clindamycin	85	15	–

Table 6. *Streptococcus pyogenes* susceptibility to current antibiotics.

	Resistant %	Sensitive %	Intermediate %
Oxacillin	–	100	–
Vancomycin	–	100	–
Trimethophrim	–	100	–
Amikacin	100	–	–
Gentamicin	–	100	–
Tetracycline	–	100	–
Rifampicin	–	100	–
Ciprofloxacin	–	100	–
Erythromycin	–	100	–
Clindamycin	–	100	–

Table 7. *Streptococcus agalactiae* susceptibility to current antibiotics.

5

	Resistant %	Sensitive %	Intermediate %
Oxacillin	–	100	–
Vancomycin	–	100	–
Trimethophrim	–	100	–
Amikacin	100	–	–
Gentamicin	100	–	–
Tetracycline	90	10	–
Rifampicin	–	100	–
Ciprofloxacin	–	100	–
Erythromycin	–	100	–
Clindamycin	–	100	–

Table 8. *Listeria monocytogenes* susceptibility to current antibiotics.

	Resistant %	Sensitive %	Intermediate %
Oxacillin	100	-	-
Vancomycin	-	100	-
Trimethophrim	-	100	-
Amikacin	-	100	-
Gentamicin	-	100	-
Tetracycline	-	100	-
Rifampicin	-	100	-
Ciprofloxacin	-	100	-
Erythromycin	-	100	-
Clindamycin	100	-	-

As shown in Table 4, all the MRSA strains used are still
 5 completely susceptible to vancomycin. However, vancomycin
 intermediate and resistant strains are now emerging (Hiramatsu,
 K., *American Journal of Medicine*, **104(5A)**, 7S-10S (1998); Quirk,
 M., *The Lancet infectious diseases*, **2**, 510 (2002)). There is no
 other antibiotic which is completely active against all strains.

10

Time-kill studies

The MRSA strain P1 was chosen to investigate the bactericidal and
 bacteriostatic activity of compound 1. The MIC value for this
 particular strain represented the MIC values obtained for the
 15 majority of the strains tested (0.015 mg/L).

Samples of the bacterial solution with ELB-21 (20µl drops, Fig.
 3a) demonstrated that at 2 hours there was no viable bacterial
 growth on the agar plates. Bacterial killing seemed to occur
 20 very rapidly and a second experiment measuring bacterial counts
 at time 0.5 and 1 hours was performed (Fig 3b). As indicated in
 the figure, after 1 hour, the bacterial counts from the MICx1


flask (0.015mg/l) were reduced to 1000 giving an approximate 3-log kill. It is generally accepted that a 3-log kill confirms bactericidal activity.

- 5 The remaining flasks with higher concentrations displayed even lower bacterial counts as would be expected. After two hours there was no bacterial growth observed from any of the flask samples, the data has not been plotted on the graphs, as the number of colonies is 0.

10

CLAIMS

1. A compound of formula I:



5

and salts and solvates thereof, wherein:


R^{10} is a nitrogen protecting group and R^{11} is either OH or O- R^{12} , wherein R^{12} is an oxygen protecting group, or R^{10} and R^{11} together form a double bond between N10 and C11;

10 and $R^{10'}$ and $R^{11'}$ are selected from the same options as R^{10} and R^{11} respectively.

2. A compound according to claim 1, wherein $R^{10'}$ and $R^{11'}$ are the same as R^{10} and R^{11} respectively.

15

3. A compound according to either claim 1 or claim 2, wherein the compounds have the following stereochemistry at the C11 position:



20 when R^{10} and R^{11} do not form a double bond.

4. A compound according to any one of claims 1 to 3, wherein the nitrogen protecting groups are selected from carbamate nitrogen protecting groups.

25

5. A compound according to claim 4, wherein the nitrogen protecting groups are selected from the group consisting of Alloc, Troc, Teoc, BOC, Doc, Hoc, TcBOC, Fmoc, 1-Adoc and 2-Adoc.

6. A compound according to claim 1 or claim 2, wherein R¹⁰ and R¹¹ together form a double bond between N10 and C11.

5

7. A compound according to any one of claims 1 to 6, wherein at least 50% is in either the E-, E- or Z-, Z- forms.

10

8. A method of synthesising a compound of any one of claims 1 to 7.

15

9. A compound of any one of claims 1 to 7 and pharmaceutically acceptable salts and solvates thereof, for use in a method of therapy.

20

10. A pharmaceutical composition comprising a compound of any one of claims 1 to 7 and pharmaceutically acceptable salts and solvates thereof, and a pharmaceutically acceptable excipient.

25

11. The use of a compound of any one of claims 1 to 7 and pharmaceutically acceptable salts and solvates thereof, in the manufacture of a medicament for the treatment of a gene-based disease.

30

12. A method for the treatment of a gene-based disease, comprising administering to a subject suffering from a gene-based disease a therapeutically-effective amount of a compound of any one of claims 1 to 7 or pharmaceutically acceptable salts and solvates thereof.

13. The use of claim 11 or the method of claim 12, wherein the gene-based disease is a proliferative disease.

35

14. The use of claim 11 or the method of claim 12, wherein the gene-based disease is infection by gram-positive bacteria.

15. The use or method of claim 14, wherein the gram-positive bacteria is selected from MRSA and VRE.

1/2




Fig. 1




Fig. 2




Fig. 3a




Fig. 3b

INTERNATIONAL SEARCH REPORT

Intern Application No
PCT/GB2005/000915

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D519/00 A61K31/5517 A61P35/00 A61P31/04
//(C07D519/00,487:00,487:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 00/12508 A (THE UNIVERSITY OF PORTSMOUTH HIGHER EDUCATION CORPORATION; THURSTON, D) 9 March 2000 (2000-03-09) cited in the application page 120, line 26 - page 122, line 6; claims 1,12,13,38-44; figures 10,11,12b; examples 2d,2e	1-15
Y	WO 00/12507 A (THE UNIVERSITY OF PORTSMOUTH HIGHER EDUCATION CORPORATION; THURSTON, D) 9 March 2000 (2000-03-09) cited in the application claims 1,19,32-37; examples 5a,5b,5c	1,9-15



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

22 July 2005

Date of mailing of the international search report

01/08/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hass, C

INTERNATIONAL SEARCH REPORT

Intern Application No
PCT/GB2005/000915

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 93/18045 A (CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED) 16 September 1993 (1993-09-16) cited in the application claims 1, 2, 11 (first occurrence), 9-11 (second occurrence), 12, 13; examples 4,6 -----	1-13
A	GREGSON S J ET AL: "Design, Synthesis, and Evaluation of a Novel Pyrrolobenzodiazepine DNA-Interactive Agent with Highly Efficient Cross-Linking Ability and Potent Cytotoxicity" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 44, no. 5, 2001, pages 737-748, XP002272009 ISSN: 0022-2623 page 739, scheme 1; page 742, column 2, line 23 - line 25 -----	1-13
A	GREGSON S J ET AL: "Synthesis of the first example of a C2-C3/C2'-C3'-endo unsaturated pyrrolo[2,1-c][1,4]benzodiazepine dimer" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 11, no. 21, 27 August 2001 (2001-08-27), pages 2859-2862, XP002329276 ISSN: 0960-894X page 2860, table 1; page 2861, scheme 2 -----	1-13
A	GREGSON S J ET AL: "SYNTHESIS OF A NOVEL C2/C2'-EXO UNSATURATED PYRROLOBENZODIAZEPINE CROSS-LINKING AGENT WITH REMARKABLE DNA BINDING AFFINITY AND CYTOTOXICITY" CHEMICAL COMMUNICATIONS - CHEMCOM, ROYAL SOCIETY OF CHEMISTRY, GB, no. 9, 1999, pages 797-798, XP001156959 ISSN: 1359-7345 the whole document ----- -/--	1-13

INTERNATIONAL SEARCH REPORT

Intern al Application No
PCT/GB2005/000915

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>KAMAL A ET AL: "Synthesis of pyrrolo'2,1-c!'1,4!benzodiazepines via reductive cyclization of omega-azido carbonyl compounds by TMSI: an efficient preparation of antibiotic DC-81 and its dimers"</p> <p>BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 10, no. 20, 16 October 2000 (2000-10-16), pages 2311-2313, XP004224207 ISSN: 0960-894X page 2311, left-hand column, first paragraph; page 2312, scheme 2</p> <p>-----</p>	1-13
A	<p>SAGNOU M J ET AL: "Design and synthesis of novel pyrrolobenzodiazepine (PBD) prodrugs for ADEPT and GDEPT"</p> <p>BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 10, no. 18, September 2000 (2000-09), pages 2083-2086, XP004208317 ISSN: 0960-894X page 2083, left-hand column, first paragraph; page 2084, scheme 2</p> <p>-----</p>	1-5,7-13
A	<p>THURSTON D E ET AL: "Synthesis of Sequence-Selective C8-Linked Pyrrolo'2,1-c!'1,4!benzodiazepine DNA Interstrand Cross-Linking Agents"</p> <p>JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 61, no. 23, 1996, pages 8141-8147, XP002272010 ISSN: 0022-3263 page 8142, scheme 1</p> <p>-----</p>	1-8

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claim 12 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. Moreover, as far as claims 13-15 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

In international application No.
PCT/GB2005/000915

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Interr il Application No
PC1/GB2005/000915

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0012508	A	09-03-2000	AT 240334 T	15-05-2003
			AT 294803 T	15-05-2005
			AU 757510 B2	20-02-2003
			AU 5635199 A	21-03-2000
			CA 2341471 A1	09-03-2000
			DE 69907977 D1	18-06-2003
			DE 69907977 T2	22-07-2004
			DE 69925133 D1	09-06-2005
			DK 1193270 T3	15-09-2003
			EP 1193270 A2	03-04-2002
			EP 1413582 A1	28-04-2004
			EP 1109812 A2	27-06-2001
			ES 2199200 T3	16-02-2004
			WO 0012508 A2	09-03-2000
			JP 2002525285 T	13-08-2002
			NZ 510493 A	28-11-2003
			PT 1193270 T	31-10-2003
			US 2003120069 A1	26-06-2003
WO 0012507	A	09-03-2000	AT 246687 T	15-08-2003
			AU 758398 B2	20-03-2003
			AU 5526199 A	21-03-2000
			CA 2341968 A1	09-03-2000
			DE 69910227 D1	11-09-2003
			DE 69910227 T2	17-06-2004
			DK 1109811 T3	24-11-2003
			EP 1109811 A2	27-06-2001
			ES 2205872 T3	01-05-2004
			WO 0012507 A2	09-03-2000
			JP 2002525284 T	13-08-2002
			NZ 510492 A	29-08-2003
			PT 1109811 T	31-12-2003
			US 2003195196 A1	16-10-2003
			US 6562806 B1	13-05-2003
WO 9318045	A	16-09-1993	AU 3643593 A	05-10-1993
			WO 9318045 A1	16-09-1993
			ZA 9301637 A	04-10-1993